Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

Impaired Pten expression in human malignant peripheral nerve sheath tumours.

Bradtmöller M, Hartmann C, Zietsch J, Jäschke S, Mautner VF, Kurtz A, Park SJ, Baier M, Harder A, Reuss D, von Deimling A, Heppner FL, Holtkamp N.

PLoS One. 2012;7(11):e47595. doi: 10.1371/journal.pone.0047595. Epub 2012 Nov 6.

2.

PTEN and NF1 inactivation in Schwann cells produces a severe phenotype in the peripheral nervous system that promotes the development and malignant progression of peripheral nerve sheath tumors.

Keng VW, Rahrmann EP, Watson AL, Tschida BR, Moertel CL, Jessen WJ, Rizvi TA, Collins MH, Ratner N, Largaespada DA.

Cancer Res. 2012 Jul 1;72(13):3405-13. doi: 10.1158/0008-5472.CAN-11-4092. Epub 2012 Jun 14.

3.

Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor.

Zou CY, Smith KD, Zhu QS, Liu J, McCutcheon IE, Slopis JM, Meric-Bernstam F, Peng Z, Bornmann WG, Mills GB, Lazar AJ, Pollock RE, Lev D.

Mol Cancer Ther. 2009 May;8(5):1157-68. doi: 10.1158/1535-7163.MCT-08-1008. Epub 2009 May 5.

4.

Transgenic mice overexpressing neuregulin-1 model neurofibroma-malignant peripheral nerve sheath tumor progression and implicate specific chromosomal copy number variations in tumorigenesis.

Kazmi SJ, Byer SJ, Eckert JM, Turk AN, Huijbregts RP, Brossier NM, Grizzle WE, Mikhail FM, Roth KA, Carroll SL.

Am J Pathol. 2013 Mar;182(3):646-67. doi: 10.1016/j.ajpath.2012.11.017. Epub 2013 Jan 13.

5.

NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.

Park HJ, Lee SJ, Sohn YB, Jin HS, Han JH, Kim YB, Yim H, Jeong SY.

Int J Oncol. 2013 Feb;42(2):657-66. doi: 10.3892/ijo.2012.1751. Epub 2012 Dec 24.

PMID:
23292448
6.

Preclinical in vivo evaluation of rapamycin in human malignant peripheral nerve sheath explant xenograft.

Bhola P, Banerjee S, Mukherjee J, Balasubramanium A, Arun V, Karim Z, Burrell K, Croul S, Gutmann DH, Guha A.

Int J Cancer. 2010 Jan 15;126(2):563-71. doi: 10.1002/ijc.24783.

7.

RAS/MEK-independent gene expression reveals BMP2-related malignant phenotypes in the Nf1-deficient MPNST.

Sun D, Haddad R, Kraniak JM, Horne SD, Tainsky MA.

Mol Cancer Res. 2013 Jun;11(6):616-27. doi: 10.1158/1541-7786.MCR-12-0593. Epub 2013 Feb 19.

8.

PTEN dosage is essential for neurofibroma development and malignant transformation.

Gregorian C, Nakashima J, Dry SM, Nghiemphu PL, Smith KB, Ao Y, Dang J, Lawson G, Mellinghoff IK, Mischel PS, Phelps M, Parada LF, Liu X, Sofroniew MV, Eilber FC, Wu H.

Proc Natl Acad Sci U S A. 2009 Nov 17;106(46):19479-84. doi: 10.1073/pnas.0910398106. Epub 2009 Oct 21.

9.

Translationally controlled tumor protein is a novel biological target for neurofibromatosis type 1-associated tumors.

Kobayashi D, Hirayama M, Komohara Y, Mizuguchi S, Wilson Morifuji M, Ihn H, Takeya M, Kuramochi A, Araki N.

J Biol Chem. 2014 Sep 19;289(38):26314-26. doi: 10.1074/jbc.M114.568253. Epub 2014 Aug 4.

10.

Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours.

Subramanian S, Thayanithy V, West RB, Lee CH, Beck AH, Zhu S, Downs-Kelly E, Montgomery K, Goldblum JR, Hogendoorn PC, Corless CL, Oliveira AM, Dry SM, Nielsen TO, Rubin BP, Fletcher JA, Fletcher CD, van de Rijn M.

J Pathol. 2010 Jan;220(1):58-70. doi: 10.1002/path.2633.

11.

Subclassification of nerve sheath tumors by gene expression profiling.

Holtkamp N, Reuss DE, Atallah I, Kuban RJ, Hartmann C, Mautner VF, Frahm S, Friedrich RE, Algermissen B, Pham VA, Prietz S, Rosenbaum T, Estevez-Schwarz L, von Deimling A.

Brain Pathol. 2004 Jul;14(3):258-64.

PMID:
15446580
12.

Methylation-based classification of benign and malignant peripheral nerve sheath tumors.

Röhrich M, Koelsche C, Schrimpf D, Capper D, Sahm F, Kratz A, Reuss J, Hovestadt V, Jones DT, Bewerunge-Hudler M, Becker A, Weis J, Mawrin C, Mittelbronn M, Perry A, Mautner VF, Mechtersheimer G, Hartmann C, Okuducu AF, Arp M, Seiz-Rosenhagen M, Hänggi D, Heim S, Paulus W, Schittenhelm J, Ahmadi R, Herold-Mende C, Unterberg A, Pfister SM, von Deimling A, Reuss DE.

Acta Neuropathol. 2016 Jun;131(6):877-87. doi: 10.1007/s00401-016-1540-6. Epub 2016 Feb 8.

PMID:
26857854
13.

Molecular evolution of a neurofibroma to malignant peripheral nerve sheath tumor (MPNST) in an NF1 patient: correlation between histopathological, clinical and molecular findings.

Spurlock G, Knight SJ, Thomas N, Kiehl TR, Guha A, Upadhyaya M.

J Cancer Res Clin Oncol. 2010 Dec;136(12):1869-80. doi: 10.1007/s00432-010-0846-3. Epub 2010 Mar 15.

PMID:
20229272
14.

MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors.

Holtkamp N, Atallah I, Okuducu AF, Mucha J, Hartmann C, Mautner VF, Friedrich RE, Mawrin C, von Deimling A.

Neoplasia. 2007 Aug;9(8):671-7.

15.
16.

Sensitivity of malignant peripheral nerve sheath tumor cells to TRAIL is augmented by loss of NF1 through modulation of MYC/MAD and is potentiated by curcumin through induction of ROS.

Reuss DE, Mucha J, Hagenlocher C, Ehemann V, Kluwe L, Mautner V, von Deimling A.

PLoS One. 2013;8(2):e57152. doi: 10.1371/journal.pone.0057152. Epub 2013 Feb 21.

17.

PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor.

Perrone F, Da Riva L, Orsenigo M, Losa M, Jocollè G, Millefanti C, Pastore E, Gronchi A, Pierotti MA, Pilotti S.

Neuro Oncol. 2009 Dec;11(6):725-36. doi: 10.1215/15228517-2009-003.

18.
19.

Whole-exome sequencing of breast cancer, malignant peripheral nerve sheath tumor and neurofibroma from a patient with neurofibromatosis type 1.

McPherson JR, Ong CK, Ng CC, Rajasegaran V, Heng HL, Yu WS, Tan BK, Madhukumar P, Teo MC, Ngeow J, Thike AA, Rozen SG, Tan PH, Lee AS, Teh BT, Yap YS.

Cancer Med. 2015 Dec;4(12):1871-8. doi: 10.1002/cam4.551. Epub 2015 Oct 3.

20.

Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.

Johansson G, Mahller YY, Collins MH, Kim MO, Nobukuni T, Perentesis J, Cripe TP, Lane HA, Kozma SC, Thomas G, Ratner N.

Mol Cancer Ther. 2008 May;7(5):1237-45. doi: 10.1158/1535-7163.MCT-07-2335.

Supplemental Content

Support Center